


Vidac Pharma Announces Broad U.S. Patent Claim Allowance for HK2-Detaching Compounds in Cancer Treatment

Notice of Allowance Covers Compounds, Compositions, and Methods for Treating HK2-Expressing Cancers

LONDON, UNITED KINGDOM, September 30, 2025 / EINPresswire.com/ -- Vidac Pharma Holdings Plc. a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announced that the United States Patent and Trademark



Office (USPTO) has issued a Notice of Allowance for U.S. Patent entitled "Use of Hexokinase 2/Mitochondria-Detaching Compounds for Treating Hexokinase-2 (HK2)-Expressing Cancers." The claims provide broad protection for Vidac's proprietary technology, covering a wide range of HK2/VDAC1 detaching compounds in mitochondria, pharmaceutical compositions containing



The broad scope of protection reflects the novelty and potential of our Mitochondrial targeting approach, and positions Vidac at the forefront of cancer metabolism therapeutics."

Dr. Max Herzberg

such compounds, and methods of treating, inhibiting, or suppressing any cancer that expresses HK2, a key driver of tumor metabolism and survival.

This allowance significantly broadens Vidac's intellectual property rights, ensuring coverage across multiple compound classes, formulations, and cancer indications. It represents a major step in consolidating the Company's leadership in the development of cancer metabolism therapeutics.

Dr. Max Herzberg, CEO of Vidac Pharma, commented: "This patent allowance represents a major milestone for Vidac, significantly strengthening our IP portfolio in

oncology. The broad scope of protection reflects the novelty and potential of our Mitochondrial targeting approach, and positions Vidac at the forefront of cancer metabolism therapeutics. The role of "healthy" mitochondria in fighting cancer is now a hot subject: Vidac is curing the block of programmed death occurring in cancer cells by reversing the Warburg effect and making the

Tumor Microenvironment (TME) pro-immune again."

Max Herzberg Vidac pharma Holding Plc +972 54-425-7381 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/853614319

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.